Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 2/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | NMT1 | P30419 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4930039 | 0.85 | MAPK14 (0.58) | MAPK14HPGDFFAR1MMP13MAOA | |
| SCHEMBL4666181 | 0.85 | OPRK1 (0.61) | MAPK14HPGDFFAR1MMP13CHRM3 | |
| SCHEMBL4795082 | 0.85 | MAPK14 (0.57) | MAPK14HPGDHRH1FFAR1MMP13 | |
| SCHEMBL4933009 | 0.84 | SLC5A7 (0.57) | MAPK14HPGDFFAR1MMP13MAOA | |
| SCHEMBL15028217 | 0.83 | MMP13 (0.67) | MAPK14HPGDHRH1MMP13CHRM3 | |
| SCHEMBL4932164 | 0.82 | SLC5A7 (0.68) | MAPK14HPGDFFAR1MMP13MAOA | |
| SCHEMBL4934168 | 0.82 | MAPK14 (0.56) | MAPK14HPGDFFAR1MMP13MAOA | |
| SCHEMBL4934170 | 0.82 | MAPK14 (0.56) | MAPK14HPGDFFAR1MMP13MAOA | |
| SCHEMBL4773909 | 0.81 | POLB (0.60) | MAPK14HPGDFFAR1MMP13MAOA | |
| Hydrochloric Acid SCHEMBL4934174 | 0.81 | MAPK14 (0.55) | MAPK14HPGDFFAR1MMP13MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | claimed |
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| EP-1891065-A1 | NOVEL MCHR1 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF MCHR1 MEDIATED CONDITIONS AND DISORDERS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006130075-A1 | NOVEL MCHR1 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF MCHR1 MEDIATED CONDITIONS AND DISORDERS | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | MCHR1, MCHR2, HCRTR1 | MAPK14 2430/4885HPGD 2402/4885HRH1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.